Tilray | TRLY - Equity Capital And Reserves



Tilray reported $3.47B in Equity Capital and Reserves for its fiscal quarter ending in November of 2024.


Equity Capital And Reserves Change Date
Acasti Pharma USD 63.55M 11.41M Jun/2025
Alaunos Therapeutics USD 2.06M 661K Dec/2024
Aurora Cannabis CAD 588.68M 15.76M Jun/2025
Avita Medical AUD 4.5M 19.42M Dec/2024
Canopy Growth CAD 488.98M 102.49M Jun/2025
Cronos Group USD 1.08B 15.89M Jun/2025
Dianthus Therapeutics USD 303.08M 49.4M Jun/2025
Divis Laboratories Ltd 149.69B 12.52B Mar/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
IQVIA Holdings USD 5.78B 199M Jun/2025
Knight Therapeutics CAD 773.91M 11.11M Sep/2024
Moderna USD 9.4B 667M Jun/2025
Organigram Holdings CAD 385.5M 61.85M Jun/2025
Organon & Co USD 733M 191M Jun/2025
Revvity USD 7.64B 29.74M Mar/2025
Tectonic Therapeutic USD 283.77M 142.99M Jun/2025
Tilray USD 3.47B 5.16M Nov/2024
Viatris USD 15.57B 79.9M Jun/2025
Xeris Pharmaceuticals USD -19300000 10.32M Jun/2025